About Cytosolic arginine sensor for mTORC1 subunit 2
Cytosolic arginine sensor for mTORC1 subunit 2 (CASTOR2) is a protein
from Homo sapiens identified by UniProt accession
A6NHX0, 329 residues long.
MolForge cross-references it against 0 known binders and
23 disease associations.
Target properties
| Protein name | Cytosolic arginine sensor for mTORC1 subunit 2 |
|---|
| UniProt accession | A6NHX0 |
|---|
| Gene | CASTOR2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 329 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (23)
Diseases linked to this target (Open Targets).
- Red cell distribution width · score 0.17
- mean reticulocyte volume · score 0.17
- lymphocyte count · score 0.13
- systemic lupus erythematosus · score 0.09
- mean corpuscular volume · score 0.05
- sleep apnea · score 0.03
- age at voice drop · score 0.03
- estrogen-receptor negative breast cancer · score 0.03
- autoimmune disease · score 0.02
- breast carcinoma · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-A6NHX0-F1 | alphafold | PREDICTED | 88.56 | — |
Amino-acid sequence (329 residues)
MELHILEHRL QVASVAKESI PLFTYGLIKL AFLSSKTRCK FFSLTETPED YTIIVDEEGF LELPSSEHLS VADATWLALN VVSGGGSFSS SQPIGVTKIA KSVIAPLADQ NISVFMLSTY QTDFILVRER DLPFVTHTLS SEFTILRVVN GETVAAENLG ITNGFVKPKL VQRPVIHPLS SPSNRFCVTS LDPDTLPAVA TLLMDVMFYS NGVKDPMATG DDCGHIRFFS FSLIEGYISL VMDVQTQQRF PSNLLFTSAS GELWKMVRIG GQPLGFDECG IVAQISEPLA AADIPAYYIS TFKFDHALVP EENINGVISA LKVSQAEKH
Explore Cytosolic arginine sensor for mTORC1 subunit 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets